Crizotinib-Induced Large Bowel Perforation: A Rare Adverse Event

Authors: Zenzri Y*, Daoud N, Berrazaga Y and Boussen H

DOI: 10.23880/mjccs-16000252

Volume 4, Issue 2

Abstract

Crizotinib is a tyrosine kinase inhibitor approved for use in the treatment of anaplastic lymphoma kinase positive, advanced non-small cell lung cancer. This targeted therapy improved clinical outcome and prolonged responses. However, potentially serious adverse effects may occur. We report a case of Crizotinib-induced large bowel perforation.

Keywords: Lung cancer; Crizotinib; Bowel perforation

View PDF